中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
13期
6-7
,共2页
阿托伐他汀%缬沙坦%永久性房颤%血浆超敏C反应蛋白%N-末端脑钠肽前体水平
阿託伐他汀%纈沙坦%永久性房顫%血漿超敏C反應蛋白%N-末耑腦鈉肽前體水平
아탁벌타정%힐사탄%영구성방전%혈장초민C반응단백%N-말단뇌납태전체수평
atorvastatin%valsartan%permanent atrial fibrillation%plasma high-sensitivity C-reactive protein%precursor N- terminal pro-brain natriuretic peptide levels
目的：探讨阿托伐他汀联合缬沙坦治疗永久性房颤的临床效果以及对患者血浆超敏C反应蛋白（hs－CRP）和N－末端脑钠肽前体（NT－proBNP）水平的影响。方法将100例永久性房颤患者按随机数字表法分为观察组和对照组，各50例，对照组患者给予常规治疗，观察组在常规治疗基础上给予阿托伐他汀联合缬沙坦治疗。结果观察组治疗有效率为92.00％，明显高于对照组的80.00％（χ2=10.814，P﹤0.05）；观察组治疗后hs－CRP和NT－proBNP水平改善较对照组明显（ P﹤0.05）。结论阿托伐他汀联合缬沙坦可提高永久性房颤治疗效果，降低血清hs－CRP与NT－proBNP水平。
目的：探討阿託伐他汀聯閤纈沙坦治療永久性房顫的臨床效果以及對患者血漿超敏C反應蛋白（hs－CRP）和N－末耑腦鈉肽前體（NT－proBNP）水平的影響。方法將100例永久性房顫患者按隨機數字錶法分為觀察組和對照組，各50例，對照組患者給予常規治療，觀察組在常規治療基礎上給予阿託伐他汀聯閤纈沙坦治療。結果觀察組治療有效率為92.00％，明顯高于對照組的80.00％（χ2=10.814，P﹤0.05）；觀察組治療後hs－CRP和NT－proBNP水平改善較對照組明顯（ P﹤0.05）。結論阿託伐他汀聯閤纈沙坦可提高永久性房顫治療效果，降低血清hs－CRP與NT－proBNP水平。
목적：탐토아탁벌타정연합힐사탄치료영구성방전적림상효과이급대환자혈장초민C반응단백（hs－CRP）화N－말단뇌납태전체（NT－proBNP）수평적영향。방법장100례영구성방전환자안수궤수자표법분위관찰조화대조조，각50례，대조조환자급여상규치료，관찰조재상규치료기출상급여아탁벌타정연합힐사탄치료。결과관찰조치료유효솔위92.00％，명현고우대조조적80.00％（χ2=10.814，P﹤0.05）；관찰조치료후hs－CRP화NT－proBNP수평개선교대조조명현（ P﹤0.05）。결론아탁벌타정연합힐사탄가제고영구성방전치료효과，강저혈청hs－CRP여NT－proBNP수평。
Objective : To investigate the effect of atorvastatin combined with valsartan in the treatment of permanent atrial fibrillation and its influence on plasma high-sensitivity C-reactive protein ( hs-CRP ) and precursor N- terminal pro-brain natriuretic peptide ( NT-proBNP ) levels. Methods 100 patients with permanent atrial fibrillation were randomly divided into the observation group and the control group, 50 cases in each group. The control group was given the conventional treatment, while on this basis the observation group was given the therapy of atorvastatin combined with valsartan. The effective rates and the improvement situation of hs-CRP and NT-proBNP levels were compared between the two groups. Results The effective rate of the observation group was 92. 00%, which was significantly higher than 80. 00% in the control group, the difference was statistically significant (χ2 = 10. 814, P ﹤ 0. 05 ); the improvement of hs-CRP and NT-proBNP levels after treatment in the observation group was more significant than that in the control group, the difference was statistically significant ( P ﹤ 0. 05 ) . Conclusion Atorvastatin combined with valsartan in the treatment of per-manent atrial fibrillation can improve the therapeutic effect and reduce serum hs-CRP and NT-proBNP levels.
